← Leaderboards
Eun-Sil Shelley Hwang
University Of California San Francisco
$9,292,755
Attributed
$20,456,268
Total exposure
12
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,854,238 · 13
By mechanism
U2C$14,506,435 · 4
R01$9,785,796 · 4
UG1$3,094,644 · 1
U10$2,019,512 · 1
T32$1,811,865 · 1
K23$635,660 · 1
Top collaborators
- Daniel P Barboriak12 shared
- Jeffrey None Crawford12 shared
- Angeles Alvarez Secord12 shared
- Carlo C Maley8 shared
- David M Brizel7 shared
- Linda Sutton7 shared
- Harry Paul Erba6 shared
- Ashutosh Chilkoti5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Ann D Thor$2,457,246
- James V. Quinn$3,660,139
- Judith J. Prochaska$7,237,917
- Joe W. Gray$35,260,197
- Thea D Tlsty$18,398,021
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsClinical TrialsTumorImageMolecularResearch PersonnelBreastResourcesEvaluationMalignant Breast NeoplasmBaseClinical ResearchUniversitiesDiagnosisMemberCellsNoninfiltrating Intraductal CarcinomaBiological MarkersFosteringCommunitiesFutureInvestigationSiteFunding
Grant awards (48)
NCI National Clinical Trials Network (UG1)$406,019
UG1 · FY2025 · CA
Point-of-care cellular and molecular pathology of breast tumors on a cell phone$560,028
R01 · FY2024 · CA
NCI National Clinical Trials Network (UG1)$410,792
UG1 · FY2024 · CA
Point-of-care cellular and molecular pathology of breast tumors on a cell phone$584,964
R01 · FY2023 · CA
NCI National Clinical Trials Network (UG1)$439,350
UG1 · FY2023 · CA
Breast Pre-Cancer Atlas Center$160,662
U2C · FY2023 · CA · contact PI
Administrative Core$160,662
U2C · FY2023 · CA · contact PI
Breast Pre-Cancer Atlas Center$133,667
U2C · FY2023 · CA · contact PI
Administrative Core$133,667
U2C · FY2023 · CA · contact PI
A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery$1,055,716
R01 · FY2022 · CA
Point-of-care cellular and molecular pathology of breast tumors on a cell phone$602,938
R01 · FY2022 · CA
Tissue Tension, RANK and Breast Cancer Risk$560,769
R01 · FY2022 · CA
NCI National Clinical Trials Network (UG1)$447,677
UG1 · FY2022 · CA
Point-of-care cellular and molecular pathology of breast tumors on a cell phone$607,659
R01 · FY2021 · CA
Tissue Tension, RANK and Breast Cancer Risk$572,212
R01 · FY2021 · CA
NCI National Clinical Trials Network (UG1)$455,656
UG1 · FY2021 · CA
Extension to the HTAN Pre-Cancer Atlas Project$304,550
U2C · FY2021 · CA · contact PI
A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery$274,299
R01 · FY2021 · CA
Point-of-care cellular and molecular pathology of breast tumors on a cell phone$581,490
R01 · FY2020 · CA
Tissue Tension, RANK and Breast Cancer Risk$570,897
R01 · FY2020 · CA
NCI National Clinical Trials Network (UG1)$463,561
UG1 · FY2020 · CA
Translational Research in Surgical Oncology$338,434
T32 · FY2020 · CA
Tissue Tension, RANK and Breast Cancer Risk$551,188
R01 · FY2019 · CA
NCI National Clinical Trials Network (UG1)$471,589
UG1 · FY2019 · CA
Translational Research in Surgical Oncology$373,223
T32 · FY2019 · CA
Breast Pre-Cancer Atlas Center$10,799,091
U2C · FY2018 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$1,589,606
U2C · FY2018 · CA · contact PI
Administrative Core$1,224,530
U2C · FY2018 · CA · contact PI
Tissue Tension, RANK and Breast Cancer Risk$581,219
R01 · FY2018 · CA
Translational Research in Surgical Oncology$446,107
T32 · FY2018 · CA
NCI National Clinical Trials Network U10$413,627
U10 · FY2018 · CA
A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery$723,579
R01 · FY2017 · CA
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS$490,842
R01 · FY2017 · CA · contact PI
Translational Research in Surgical Oncology$441,040
T32 · FY2017 · CA
NCI National Clinical Trials Network U10$392,946
U10 · FY2017 · CA
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS$490,842
R01 · FY2016 · CA · contact PI
NCI National Clinical Trials Network U10$392,946
U10 · FY2016 · CA
Translational Research in Surgical Oncology$213,061
T32 · FY2016 · CA
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS$490,842
R01 · FY2015 · CA · contact PI
NCI National Clinical Trials Network U10$411,893
U10 · FY2015 · CA
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS$486,312
R01 · FY2014 · CA · contact PI
NCI National Clinical Trials Network U10$408,100
U10 · FY2014 · CA
Primary Hormonal Therapy for DCIS of the Breast$127,170
K23 · FY2008 · CA · contact PI
Primary Hormonal Therapy for DCIS of the Breast$127,170
K23 · FY2007 · CA · contact PI
Primary Hormonal Therpay for DCIS of the Breast$127,170
K23 · FY2006 · CA · contact PI
Primary Hormonal Therpay for DCIS of the Breast$127,170
K23 · FY2005 · CA
METHOD FOR MEASURING BREAST EPITHELIAL CELL TURNOVER IN HUMANS$326
M01 · FY2005 · RR
Primary Hormonal Therapy for DCIS of the Breast$126,980
K23 · FY2004 · CA